Guidance for industry accelerated approval products, submission of promotional materials.

Saved in:

Guidance for industry accelerated approval products, submission of promotional materials.

Bibliographic Details
Corporate Authors:	Center for Drug Evaluation and Research (U.S.), Center for Biologics Evaluation and Research (U.S.)
Format:	Government Document Online Book
Language:	English
Published:	Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research : Center for Biologics Evaluation and Research, [1999]
Subjects:	Drug approval > United States. Advertising > Drugs > United States.
Access:	ONLINE VERSION How to Borrow from Another Library Search for the book on EZBorrow. EZBorrow is the easiest and fastest way to get the book you want (ebooks unavailable). Use ILLiad for articles and chapter scans. Make an ILLIAD request. If your book is not available on EZBorrow, you can request it through ILLiad (ebooks unavailable). You can also use ILLiad to request chapter scans and articles.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Guidance for industry changes to an approved NDA or ANDA.
Published: (2004)

Guidance for industry submission of documentation in applications for parametric release of human and veterinary drug products terminally sterilized by moist heat processes.
Published: (2010)

Guidance for industry changes to an approved NDA or ANDA, questions and answers.
Published: (2001)

Guidance for industry submission of documentation in applications for parametric release of human and veterinary drug products terminally sterilized by moist heat processes.
Published: (2008)

Guidance for industry changes to an approved NDA or ANDA, specifications, use of enforcement discretion for compendial changes.
Published: (2004)

Guidance for industry variations in drug products that may be included in a single ANDA.
Published: (1998)

Guidance for industry Q3A impurities in new drug substances.
Published: (2008)

Guidance for industry ANDAs, impurities in drug products.
Published: (2005)

Guidance for industry NDA's : impurities in drug substances.
Published: (2000)

Guidance for industry for the submission documentation for sterilization process validation in applications for human and veterinary drug products
Published: (1994)

Guidance for industry referencing discontinued labeling for listed drugs in abbreviated new drug applications.
Published: (2000)

Guidance for industry antibacterial drug products, use of noninferiority studies to support approval.
Published: (2007)

Guidance for industry major, minor, and telephone amendments to abbreviated new drug applications.
Published: (2001)

Guidance for industry ANDAs, impurities in drug substances.
Published: (2009)

Guidance for industry comparability protocols, chemistry, manufacturing, and controls information.
Published: (2003)

Guidance for industry providing regulatory submissions in electronic format : human pharmaceutical product applications and related submissions using the eCTD specifications.
Published: (2008)

Guidance for industry revising and ANDA labeling following revision of the RLD labeling.
Published: (2000)

Guidance for industry botanical drug products.
Published: (2004)

Guidance for industry changes to an approved application for specified biotechnology and specified synthetic biological products.
Published: (1997)

Guidance for industry M4, organization of the CTD.
Published: (2001)

Guidance for industry alternate source of the active pharmaceutical ingredient in pending ANDAs.
Published: (2000)

Guidance for industry providing regulatory submissions in electronic format, general considerations.
Published: (1999)

Guidance for industry qualifying for pediatric exclusivity under section 505A of the Federal Food, Drug, and Cosmetic Act.
Published: (1999)

Guidance for industry classifying resubmissions in response to action letters.
Published: (1998)

Guidance for industry 180-day exclusivity when multiple ANDAs are submitted on the same day.
Published: (2003)

Guidance for industry M4E, the CTD, efficacy.
Published: (2001)

Guidance for industry formal dispute resolution, appeals above the division level.
Published: (2000)

Guidance for industry M2, eCTD specification, questions & answers and change requests.
Published: (2005)

Guidance for industry PET drug applications : content and format for NDAs and ANDAs, fludeoxyglucose F 18 injection, ammonia N 13 injection, sodium fluoride F 18 injection.
Published: (2000)

Guidance for industry listed drugs, 30 month stays, and approval of ANDAs and 505(b)(2) applications under Hatch-Waxman, as amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, questions and answers.
Published: (2004)

Guidance for industry presenting risk information in prescription drug and medical device promotion.
Published: (2009)

Guidance for industry and FDA staff submission and resolution of formal disputes regarding the timeliness of premarket review of a combination product.
Published: (2004)

Guidance for industry product name placement, size, and prominence in advertising and promotional labeling.
Published: (1999)

Guidance for industry court decisions, ANDA approvals, and 180-day exclusivity under the Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act.
Published: (2000)

Guidance for industry submitting marketing applications according to the ICH-CTD format, general considerations.
Published: (2001)

Guidance for industry providing regulatory submissions in electronic format, prescription drug advertising and promotional labeling.
Published: (2001)

Guidance for industry INDs for phase 2 and phase 3 studies, chemistry, manufacturing, and controls information.
Published: (2003)

Guidance for industry and FDA staff how to write a request for designation (RFD).
Published: (2005)

Guidance for industry formal meetings between the FDA and sponsors or applicants.
Published: (2009)

Guidance for industry environmental assessment of human drug and biologics applications.
Published: (1998)